Propranolol in Primary Progressive Aphasia

Description

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

Conditions

Aphasia, Primary Progressive

Study Overview

Study Details

Study overview

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

Trial of Propranolol in Older Adults With Primary Progressive Aphasia

Propranolol in Primary Progressive Aphasia

Condition
Aphasia, Primary Progressive
Intervention / Treatment

-

Contacts and Locations

Columbia

University of Missouri-Columbia, Columbia, Missouri, United States, 65212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 1. Age: 50 and older
  • * 2. Primary Progressive Aphasia diagnosis
  • * 3. Native English speaker
  • * 1. Unable to provide consent
  • * 2. Taking alpha 2 agonists (clonidine and guanfacine)
  • * 3. Other major psychological or neurological diagnosis
  • * 4. Major head trauma that contributed to their condition
  • * 5. Allergic reaction to adhesives
  • * 6. Uncorrected vision/hearing impairments
  • * 7. Diabetes
  • * 8. Reactive airway disease
  • * 9. Untreated hypothyroidism
  • * 10. Bradyarrhythmia
  • * 11. Unexplained syncope
  • * 12. Pregnancy (assessed verbally on the days of MR imaging)
  • * 13. Drugs that interact with propranolol, such as alpha 2 agonists
  • * 14. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Missouri-Columbia,

David Beversdorf, MD, PRINCIPAL_INVESTIGATOR, University of Missouri-Columbia

Study Record Dates

2026-10